Ryan P. Bingham

Ryan P. Bingham

Auto-generated profile, based on publicly available information

Ryan P. Bingham

Medicines Research Centre, GlaxoSmithKline R&D, Stevenage, United Kingdom

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JLJohn Liddle
John Liddle
VBVeronique Beneton
Veronique Beneton
MBMatthew Benson
Matthew Benson
RBRyan Bingham
Ryan Bingham
ABAnne Bouillot
Anne Bouillot
AHAlain HOVNANIAN
Alain HOVNANIAN

1 June 2021 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
LGLuke A. Greenhough
Luke A. Greenhough
GCGabriella Clarke
Gabriella Clarke
APAlexander N. Phillipou
Alexander N. Phillipou
FMFaith Mazani
Faith Mazani
BKBhumika Karamshi
Bhumika Karamshi
PCPeter D. Craggs
Peter D. Craggs
The predominant assay detection methodologies used for enzyme inhibitor identification during early-stage drug discovery are fluorescence-based. Each fluorophore has a characteristic fluorescence decay, known as the fluorescence lifetime, that occurs throughout a nanosecond-to-millisecond timescale. The measurement of fluorescence lifetime as a reporter for biological activity is less common than fluorescence intensity, even though the latter has numerous issues that can lead to false-positive readouts. The confirmation of hit compounds as true inhibitors requires additional assays, cost, and time to progress from hit identification to lead drug-candidate optimization. To explore whether the use of fluorescence lifetime technology (FLT) can offer comparable benefits to label-free-based approaches such as RapidFire mass spectroscopy (RF-MS) and a superior readout compared to time-resolved fluorescence resonance energy transfer (TR-FRET), three equivalent assays were developed against the clinically validated tyrosine kinase 2 (TYK2) and screened against annotated compound sets. FLT provided a marked decrease in the number of false-positive hits when compared to TR-FRET. Further cellular screening confirmed that a number of potential inhibitors directly interacted with TYK2 and inhibited the downstream phosphorylation of the signal transducer and activator of transcription 4 protein (STAT4).